Univariate and age-adjusted multivariate analysis of risk factors for early-onset CTRCD after HSCT
| Univariate analysis | Multivariate analysis | |||
| OR (95% CI) | P value | OR (95% CI) | P value | |
| Age | 1.00 (0.97 to 1.04) | 0.871 | ||
| Male | 0.46 (0.18 to 1.15) | 0.095 | ||
| CCr, /10 mL/min | 0.86 (0.75 to 1.00) | 0.052 | 0.88 (0.76 to 1.03) | 0.098 |
| Cardiac risk factors≥2 | 1.95 (0.56 to 6.78) | 0.292 | ||
| Cumulative DXR dose, /10 mg/m2 | 1.03 (1.00 to 1.07) | 0.058 | 1.04 (1.00 to 1.07) | 0.032 |
| RAS inhibitors or beta-blockers | 5.09 (0.31 to 84.50) | 0.256 | ||
| Leukaemia | 0.86 (0.32 to 2.30) | 0.770 | ||
| History of prior HSCT | 1.95 (0.76 to 5.00) | 0.163 | ||
| Non-CR status at HSCT | 2.13 (0.74 to 6.16) | 0.163 | ||
| Source of HSCT | 0.783 | |||
| Bone marrow (reference) | 1.00 | – | ||
| Cord blood | 1.62 (0.53 to 4.95) | – | ||
| PBSC | 1.39 (0.48 to 4.05) | – | ||
| Haploidentical PBSCT | 1.55 (0.39 to 6.12) | 0.536 | ||
| HLA mismatch ≥one locus | 2.17 (0.80 to 5.91) | 0.130 | ||
| Conditioning regimen with MAC | 0.40 (0.14 to 1.17) | 0.094 | ||
| HCT-CI, /point | 1.56 (1.02 to 2.38) | 0.042 | 1.38 (0.86 to 2.19) | 0.177 |
| GVHD prophylaxis including tacrolimus | 0.51 (0.20 to 1.29) | 0.155 | ||
| Acute GVHD, /grade | 4.42 (1.71 to 11.40) | 0.002 | 1.87 (1.19 to 2.95) | 0.004 |
CCr, creatinine clearance; CR, complete remission; CTRCD, cancer therapy-related cardiac dysfunction; DXR, doxorubicin; GVHD, graft-versus-host disease; HCT-CI, haematopoietic cell transplantation-specific comorbidity index; HLA, human leucocyte antigen; HSCT, haematopoietic stem cell transplantation; LVEF, left ventricular ejection fraction; MAC, myeloablative conditioning; PBSC, peripheral blood stem cell; PBSCT, peripheral blood stem cell transplantation; RAS, renin-angiotensin system.